TUBGCP2 and adenocarcinoma: In addition, silencing of ACRBP or TUBGCP2 in NSCLC cell lines that lack a robust spindle assembly checkpoint [e.g., HCC366 (adenosquamous), HCC15 (squamous cell) or HCC4017 (adenocarcinoma)] was sufficient to induce accumulation of non-proliferating micro-nucleated cells, which are characteristic of taxol treatment [11].